Prophylaxis in Von Willebrand disease

Annals of Hematology

Volumn 86, Issue 10, 2007, Pages 699-704

  Franchini, Massimo ^a   Targher, Giovanni ^b   Lippi, Giuseppe ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Prophylaxis; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FANHDI; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILFACTIN;

BLEEDING DISORDER; CHEMOPROPHYLAXIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; GENETIC DISORDER; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HEMOSTATICS; HUMANS; MALE; PROSPECTIVE STUDIES; TIME FACTORS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 34548314245     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0343-1     Document Type: Review

References (33)

1. Rodeghiero F, Castaman G, Dini E (1987) Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69:454-459
2. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB (2006) Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 4:2103-2114
3. Federici AB (2004) Clinical diagnosis of von Willebrand disease. Haemophilia 10(Suppl 4):169-176
4. Federici AB, Castaman G, Mannucci PM (2002) Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 8:607-621
5. Franchini M, Lippi G (2007) The role of von Willebrand factor in hemorrhagic and thrombotic disorders. Crit Rev Clin Lab Sci 44:115-149
6. Mannnucci PM (2001) How I treat patients with von Willebrand disease. Blood 97:1915-1919
7. Mannucci PM (2000) Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 6(Suppl 1):60-67
8. Mannucci PM (2004) Treatment of von Willebrand's disease. N Engl J Med 351:683-694
9. Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM (2000) Optimising local therapy during oral surgery in patients with von Willebrand disease: Effective results from a retrospective analysis of 63 cases. Haemophilia 6:71-77
10. Leissinger C, Becton D, Cornell C Jr, Cox Gill J (2001) High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 7:258-266
11. Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA (2001) Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 66:280-284
12. Lillicrap D, Poon M-C, Walker I, Xie F, Schwartz BA (2002) Efficacy and safety of the factor VIII/von Willebrand Factor concentrate, Haemate-P/ Humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 87:224-230
13. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G (2003) Efficacy and safety of factor VIII/von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand's disease. Haematologica 88:1279-1283
14. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA (2004) Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/von Willebrand factor concentrate (Humate-P). Haemophilia 10:42-51
15. Bernstein J, Cox Gill J, Leissinger CA, Di Paola J, Ragni MV, Shopnick R, Valentino RA, Friedman C, Knaub S (2006) Safety and efficacy of von Willebrand factor/factor VIII concentrate (Humate-P) for prophylaxis of excessive bleeding during elective surgery in patients with von Willebrand disease. Blood 108:4076 Abstract
16. Federici AB, Castaman G, Franchini M, Morfini M, Zanon E, Coppola A, Tagliaferri A, Boeri E, Mazzucconi MG, Rossetti G, Mannucci PM (2007) Clinical use of Haemate P in inherited von Willebrand disease: A cohort study on 100 Italian patients. Haematologica 92:944-951
17. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; the Haemate P Surgical Study Group (2007) Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost 5:1420-1430
18. Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannucci PM (2002) Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: A retrospective clinical study. Haemophilia 8:761-767
19. Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 99:450-456
20. Goudemand J, Negrier C, Ounnoughene N, Sultan Y (1998) Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: The French experience. Haemophilia 4(Suppl 3):48-52
21. Ewenstein BM (2001) Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 7(Suppl 1):10-15
22. Laffan M, Brown SA, Collins PW, Cumming AM, Hill FG, Keeling D, Peake IR, Pasi KJ (2004) The diagnosis of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 10:199-217
23. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343:457-462
24. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): A prospective study of 50 patients. J Thromb Haemost 5:1115-1124
25. Abshire TC (2006) Prophylaxis and von Willebrand's disease. Thromb Res 118S1:S3-S7
26. Makris M (2006) Gastrointestinal bleeding in von Willebrand disease. Thromb Res 118S1:S13-S17
27. Lethagen S (2006) Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 118S1:S9-S11
28. Berntorp E, Petrini P (2005) Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 16(Suppl 1):S23-S26
29. Federici AB, Gianniello F, Canciani MT, Mannucci PM (2005) Secondary long-term prophylaxis in severe patients with von Willebrand's disease: an Italian cohort study. Blood 106:507a Abstract 1782
30. Coppola A, Cimino E, Conca P, Simone C, Tufano A, Tarantino G, Cerbone AM, Minno G (2006) Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding. Haemophilia 12:90-94
31. Franchini M, Giuffrida A, Gandini G (2005) Efficacy of Haemate-P as prophylaxis of recurrent bleeding in a patient with type 2B von Willebrand's disease. Blood Coagul Fibrinolysis 16:571-572
32. Traivaree C, Blanchette V, Hilliard P, Stain A, Floros G, Carcao M (2006) Type 3 VWD: Clinical manifestations and the need for prophylaxis. Haemophilia 12(Suppl 2):918 Abstract
33. Berntorp E, Abshire T (2006) The von Willebrand Disease prophylaxis network (vWD PN): Exploring a treatment concept. Thromb Res 118S1:S19-S22